AMPK as a metabolic tumor suppressor: Control of metabolism and cell growth

Future Oncology

Volumn 6, Issue 3, 2010, Pages 457-470

  Luo, Zhijun ^a   Zang, Mengwei ^a   Guo, Wen ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetyl CoA carboxylase; AMPK; Fatty acid synthase; LKB1; Metabolic syndrome; Metabolism; MTOR; P53; Tumor suppressor; Tumorigenesis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ACETYL COENZYME A CARBOXYLASE; B RAF KINASE; CHOLESTEROL; FATTY ACID SYNTHASE; GLUCOSE TRANSPORTER 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHENFORMIN; PROTEIN KINASE LKB1; PROTEIN P53; SULFONYLUREA;

BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CELL METABOLISM; CHOLESTEROL SYNTHESIS; DOWNSTREAM PROCESSING; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN SENSITIVITY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC REGULATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; ENERGY METABOLISM; GENES, TUMOR SUPPRESSOR; HUMANS; METABOLIC SYNDROME X; NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 77949462458     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.174     Document Type: Review

References (124)

1. Steinberg GR, Kemp BE: AMPK in health and Disease. Physiol. Rev. 89(3), 1025-1078 (2009).
2. Ruderman N, Prentki M: AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat. Rev. Drug Discov. 3(4), 340-351 (2004).
3. Luo Z, Saha AK, Xiang X, Ruderman NB: AMPK, the metabolic syndrome and cancer. Trends Pharmacol. Sci. 26(2), 69-76 (2005).
4. Hoyer-Hansen M, Jaattela M: AMP-activated protein kinase: a universal regulator of autophagy? Autophagy 3(4), 381-383 (2007).
5. Shackelford DB, Shaw RJ: The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9(8), 563-575 (2009).
6. Wang W, Guan KL: AMP-activated protein kinase and cancer. Acta Physiol. (Oxf.) 196(1), 55-63 (2009).
7. Jansen M, Ten Klooster JP, Offerhaus GJ, Clevers H: LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol. Rev. 89(3), 777-798 (2009).
8. Hardie DG: AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 8(10), 774-785 (2007).
9. Carling D, Sanders MJ, Woods A: The regulation of AMP-activated protein kinase by upstream kinases. Int. J. Obes. (Lond). 32(Suppl. 4), S55-S59 (2008).
10. Davies SP, Helps NR, Cohen PT, Hardie DG: 5́-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C a and native bovine protein phosphatase-2AC. FEBS Lett. 377(3), 421-425 (1995).
11. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D: Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J. 403(1), 139-148 (2007).
12. Woods A, Johnstone SR, Dickerson K et al.: LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13(22), 2004-2008 (2003).
13. Hawley SA, Boudeau J, Reid JL et al.: Complexes between the LKB1 tumor suppressor, STRAD a/b and MO25 a/b are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2(4), 28 (2003).
14. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, Neumann D: Dissecting the role of 5́-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J. Biol. Chem. 281(43), 32207-32216 (2006).
15. Zhang BB, Zhou G, Li C: AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 9(5), 407-416 (2009).
16. Minokoshi Y, Kim YB, Peroni OD et al.: Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415(6869), 339-343 (2002).
17. Minokoshi Y, Alquier T, Furukawa N et al.: AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428(6982), 569-574 (2004).
18. Hong SP, Leiper FC, Woods A, Carling D, Carlson M: Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc. Natl Acad. Sci. USA 100(15), 8839-8843 (2003).
19. Shaw RJ, Kosmatka M, Bardeesy N et al.: The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA 101(10), 3329-3335 (2004).
20. Hawley SA, Pan DA, Mustard KJ et al.: Calmodulin-dependent protein kinase kinase-b is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2(1), 9-19 (2005).
21. 2+/calmodulin- dependent protein kinase kinase-b acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2(1), 21-33 (2005).
22. Xie M, Zhang D, Dyck JR et al.: A pivotal role for endogenous TGF-b-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl Acad. Sci. USA 103(46), 17378-17383 (2006).
23. Momcilovic M, Hong SP, Carlson M: Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 281(35), 25336-25343 (2006).
24. Suzuki A, Kusakai G, Kishimoto A et al.: IGF-1 phosphorylates AMPK-a subunit in ATM-dependent and LKB1-independent manner. Biochem. Biophys. Res. Commun. 324(3), 986-992 (2004).
25. Herrero-Martin G, Hoyer-Hansen M, Garcia-Garcia C, Fumarola C, Farkas T, Lopez-Rivas A et al.: TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 28(6), 677-685 (2009).
26. Alessi DR, Sakamoto K, Bayascas JR: LKB1-dependent signaling pathways. Annu. Rev. Biochem. 75, 137-163 (2006).
27. Sanchez-Cespedes M, Parrella P, Esteller M et al.: Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62(13), 3659-3662 (2002).
28. Ji H, Ramsey MR, Hayes DN et al.: LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155), 807-810 (2007).
29. Wingo SN, Gallardo TD, Akbay EA et al.: Somatic LKB1 mutations promote cervical cancer progression. PLoS One 4(4), E5137 (2009).
30. Ikediobi ON, Davies H, Bignell G et al.: Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5(11), 2606-2612 (2006).
31. Gurumurthy S, Hezel AF, Sahin E, Berger JH, Bosenberg MW, Bardeesy N: LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res. 68(1), 55-63 (2008).
32. Contreras CM, Gurumurthy S, Haynie JM et al.: Loss of LKB1 provokes highly invasive endometrial adenocarcinomas. Cancer Res. 68(3), 759-766 (2008).
33. Pearson HB, McCarthy A, Collins CM, Ashworth A, Clarke AR: LKB1 deficiency causes prostate neoplasia in the mouse. Cancer Res. 68(7), 2223-2232 (2008).
34. Huang X, Wullschleger S, Shpiro N et al.: Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 412(2), 211-221 (2008).
35. Carretero J, Medina PP, Blanco R et al.: Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 26(11), 1616-1625 (2007).
36. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z: AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem. Biophys. Res. Commun. 321(1), 161-167 (2004).
37. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS: AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J. Biol. Chem. 277(27), 23977-23980 (2002).
38. Horman S, Browne G, Krause U et al.: Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr. Biol. 12(16), 1419-1423 (2002).
39. Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12(1), 9-22 (2007).
40. Gomez MR: Phenotypes of the tuberous sclerosis complex with a revision of diagnostic criteria. Ann. NY Acad. Sci. 615, 1-7 (1991).
41. Inoki K, Ouyang H, Zhu T et al.: TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126(5), 955-968 (2006).
42. Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell 115(5), 577-590 (2003).
43. Gwinn DM, Shackelford DB, Egan DF et al.: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30(2), 214-226 (2008).
44. Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9(8), 550-562 (2009).
45. Porstmann T, Santos CR, Griffiths B et al.: SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8(3), 224-236 (2008).
46. Shackelford DB, Vasquez DS, Corbeil J et al.: mTOR and HIF-1a-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl Acad. Sci. USA 106(27), 11137-11142 (2009).
47. Shaw RJ, Bardeesy N, Manning BD et al.: The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6(1), 91-99 (2004).
48. Jones RG, Plas DR, Kubek S et al.: AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18(3), 283-293 (2005).
49. Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H: Cell cycle regulation via p53 phosphorylation by a 5́-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun. 287(2), 562-567 (2001).
50. Zhou J, Huang W, Tao R et al.: Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene 28(18), 1993-2002 (2009).
51. Feng Z, Hu W, de Stanchina E et al.: The regulation of AMPK b1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 67(7), 3043-3053 (2007).
52. Budanov AV, Karin M: p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134(3), 451-460 (2008).
53. Yang W, Hong YH, Shen XQ, Frankowski C, Camp HS, Leff T: Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors. J. Biol. Chem. 276(42), 38341-38344 (2001).
54. Greer EL, Oskoui PR, Banko MR et al.: The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J. Biol. Chem. 282(41), 30107-30119 (2007).
55. Liang J, Shao SH, Xu ZX et al.: The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 9(2), 218-224 (2007).
56. Short JD, Houston KD, Dere R et al.: AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res. 68(16), 6496-6506 (2008).
57. Katz MS: Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat. Clin. Pract. Oncol. 2(2), 82-89 (2005).
58. Farwell WR, Scranton RE, Lawler EV et al.: The association between statins and cancer incidence in a veterans population. J. Natl Cancer Inst. 100(2), 134-139 (2008).
59. Kuhajda FP: Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16(3), 202-208 (2000).
60. Baron A, Migita T, Tang D, Loda M: Fatty acid synthase: a metabolic oncogene in prostate cancer? J. Cell Biochem. 91(1), 47-53 (2004).
61. Zhou G, Myers R, Li Y et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108(8), 1167-1174 (2001).
62. Thupari JN, Pinn ML, Kuhajda FP: Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun. 285(2), 217-223 (2001).
63. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV: RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 63(13), 3799-3804 (2003).
64. Zhou W, Han WF, Landree LE et al.: Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res. 67(7), 2964-2971 (2007).
65. Zang M, Xu S, Maitland-Toolan KA et al.: Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55(8), 2180-2191 (2006).
66. Bandyopadhyay GK, Yu JG, Ofrecio J, Olefsky JM: Increased malonyl-CoA levels in muscle from obese and Type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 55(8), 2277-2285 (2006).
67. Sriwijitkamol A, Coletta DK, Wajcberg E et al.: Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with Type 2 diabetes: a time-course and dose-response study. Diabetes 56(3), 836-848 (2007).
68. Kraegen EW, Saha AK, Preston E et al.: Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. Am. J. Physiol. Endocrinol. Metab. 290(3), E471-E479 (2006).
69. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348(17), 1625-1638 (2003).
70. LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S: Obesity and Type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp. Clin. Endocrinol. Diabetes 116(Suppl. 1), S4-S6 (2008).
71. Nawroth P: Diabetes, obesity, insulin resistance: different pathways to cancer? Exp. Clin. Endocrinol. Diabetes 117(10), 561-562 (2009).
72. Percik R, Stumvoll M: Obesity and cancer. Exp. Clin. Endocrinol. Diabetes 117(10), 563-566 (2009).
73. Yakar S, Nunez NP, Pennisi P et al.: Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology 147(12), 5826-5834 (2006).
74. Nunez NP, Oh WJ, Rozenberg J et al.: Accelerated tumor formation in a fatless mouse with Type 2 diabetes and inflammation. Cancer Res. 66(10), 5469-5476 (2006).
75. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, Leroith D: Insulin sensitizing therapy attenuates Type 2 diabetes-mediated mammary tumor progression. Diabetes DOI: 10.2337/db09-1291 (2009) (Epub ahead of print).
76. Kim CH, Pennisi P, Zhao H et al.: MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness. Am. J. Physiol. Endocrinol. Metab. 291(2), E298-E305 (2006).
77. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503), 1304-1305 (2005).
78. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM: New users of metformin are at low risk of incident cancer: a cohort study among people with Type 2 diabetes. Diabetes Care 32(9), 1620-1625 (2009).
79. Bowker SL, Majumdar SR, Veugelers P, Johnson JA: Increased cancer-related mortality for patients with Type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care 29(8), 1990-1991 (2006).
80. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS: Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am. J. Clin. Nutr. 86(3), S858-S866 (2007).
81. Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP: Effects of adiponectin on breast cancer cell growth and signaling. Br. J. Cancer 98(2), 370-379 (2008).
82. Kim KY, Baek A, Hwang JE et al.: Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res. 69(9), 4018-4026 (2009).
83. Sugiyama M, Takahashi H, Hosono K et al.: Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int. J. Oncol. 34(2), 339-344 (2009).
84. Jiang W, Zhu Z, Thompson HJ: Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res. 68(13), 5492-5499 (2008).
85. Rattan R, Giri S, Singh AK, Singh I: 5-Aminoimidazole-4-carboxamide-1-b- D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem. 280(47), 39582-39593 (2005).
86. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67(22), 10804-10812 (2007).
87. Buzzai M, Jones RG, Amaravadi RK et al.: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67(14), 6745-6752 (2007).
88. Horman S, Vertommen D, Heath R et al.: Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase a-subunits in heart via hierarchical phosphorylation of Ser485/491. J. Biol. Chem. 281(9), 5335-5340 (2006).
89. Hallstrom TC, Mori S, Nevins JR: An E2F1- dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13(1), 11-22 (2008).
90. Hadad SM, Baker L, Quinlan PR et al.: Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 9, 307 (2009).
91. Conde E, Suarez-Gauthier A, Garcia-Garcia E et al.: Specific pattern of LKB1 and phospho-acetyl-CoA carboxylase protein immunostaining in human normal tissues and lung carcinomas. Hum. Pathol. 38(9), 1351-1360 (2007).
92. Zheng B, Jeong JH, Asara JM et al.: Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 33(2), 237-247 (2009).
93. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA: Uncoupling of the LKB1-AMPKa energy sensor pathway by growth factors and oncogenic BRAF. PLoS One 4(3), E4771 (2009).
94. Davies H, Bignell GR, Cox C et al.: Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002).
95. Bos JL: ras oncogenes in human cancer: a review. Cancer Res. 49(17), 4682-4689 (1989).
96. Costanzo-Garvey DL, Pfluger PT, Dougherty MK et al.: KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab. 10(5), 366-378 (2009).
97. Kortum RL, Lewis RE: The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol. Cell Biol. 24(10), 4407-4416 (2004).
98. Dougherty MK, Ritt DA, Zhou M et al.: KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals. Mol. Cell 34(6), 652-662 (2009).
99. Claperon A, Therrien M: KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Oncogene 26(22), 3143-3158 (2007).
100. Warburg O: On respiratory impairment in cancer cells. Science 124(3215), 269-270 (1956).
101. Kroemer G, Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13(6), 472-482 (2008).
102. Gogvadze V, Orrenius S, Zhivotovsky B: Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 18(4), 165-173 (2008).
103. Kaelin WG Jr, Ratcliffe PJ: Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30(4), 393-402 (2008).
104. Pelicano H, Martin DS, Xu RH, Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 25(34), 4633-4646 (2006).
105. Shaw RJ: Glucose metabolism and cancer. Curr. Opin. Cell Biol. 18(6), 598-608 (2006).
106. Marsin AS, Bouzin C, Bertrand L, Hue L: The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J. Biol. Chem. 277(34), 30778-30783 (2002).
107. Hwang JT, Lee M, Jung SN et al.: AMP-activated protein kinase activity is required for vanadate-induced hypoxia-inducible factor 1a expression in DU145 cells. Carcinogenesis 25(12), 2497-2507 (2004).
108. Lee M, Hwang JT, Yun H et al.: Critical roles of AMP-activated protein kinase in the carcinogenic metal-induced expression of VEGF and HIF-1 proteins in DU145 prostate carcinoma. Biochem. Pharmacol. 72(1), 91-103 (2006).
109. Bensaad K, Vousden KH: p53: new roles in metabolism. Trends Cell Biol. 17(6), 286-291 (2007).
110. Matoba S, Kang JG, Patino WD et al.: p53 regulates mitochondrial respiration. Science 312(5780), 1650-1653 (2006).
111. Green DR, Chipuk JE: p53 and metabolism: Inside the TIGAR. Cell 126(1), 30-32 (2006).
112. Kondoh H, Lleonart ME, Gil J et al.: Glycolytic enzymes can modulate cellular life span. Cancer Res. 65(1), 177-185 (2005).
113. Richter EA, Ruderman NB: AMPK and the biochemistry of exercise: implications for human health and disease. Biochem. J. 418(2), 261-275 (2009).
114. Lamontagne J, Pepin E, Peyot ML et al.: Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic b-cell at submaximal glucose concentrations. Endocrinology 150(8), 3465-3474 (2009).
115. De Leo V, La Marca A, Orvieto R, Morgante G: Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85(4), 1598-1600 (2000).
116. Tsuboi T, da Silva Xavier G, Leclerc I, Rutter GA: 5́-AMP-activated protein kinase controls insulin-containing secretory vesicle dynamics. J. Biol. Chem. 278(52), 52042-52051 (2003).
117. Rutter GA, Da Silva Xavier G, Leclerc I: Roles of 5́-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem. J. 375(Pt 1), 1-16 (2003).
118. da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA: Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem. J. 371(Pt 3), 761-774 (2003).
119. Jiralerspong S, Palla SL, Giordano SH et al.: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27(20), 3297-3302 (2009).
120. Goodwin PJ, Ligibel JA, Stambolic V: Metformin in breast cancer: time for action. J. Clin. Oncol. 27(20), 3271-3273 (2009).
121. Kim HS, Hwang JT, Yun H et al.: Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. J. Biol. Chem. 283(7), 3731-3742 (2008).
122. Okoshi R, Ozaki T, Yamamoto H et al.: Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J. Biol. Chem. 283(7), 3979-3987 (2008).
123. Viollet B, Athea Y, Mounier R et al.: AMPK: Lessons from transgenic and knockout animals. Front. Biosci. 14, 19-44 (2009).
124. Suzuki A, Lu J, Kusakai G, Kishimoto A, Ogura T, Esumi H: ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol. Cell Biol. 24(8), 3526-3535 (2004).